Physician profile
Roy Blumenstrauch
NPI 1639175409
$2,945.69
in general payments reported to CMS, 2019-2025
26 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $945 · 2020: $424 · 2021: $347 · 2022: $452 · 2023: $246 · 2024: $215 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.69 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.37 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $361.71 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $263.04 | 2020-2024 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $160.03 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $123.54 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $114.44 | 2019-2025 | |
| Pfizer INC. | $113.96 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.77 | 2019-2021 | |
| Incyte Corporation | $96.27 | 2021-2024 | Opzelura |
| Sandoz INC. | $92.60 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $75.30 | 2022-2023 | Dupixent |
| Almirall LLC | $74.34 | 2020-2022 | |
| Allergan, INC. | $68.44 | 2019-2020 | |
| Biofrontera INC. | $59.85 | 2019-2022 | |
| Lilly USA, LLC | $51.62 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $41.98 | 2019 | |
| Janssen Scientific Affairs, LLC | $39.44 | 2019-2020 | |
| Leo Pharma INC. | $37.74 | 2019-2021 | |
| Strata Skin Sciences, INC. | $34.88 | 2021-2022 | |
| Organon LLC | $26.64 | 2025 | Vtama |
| Celgene Corporation | $24.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.51 | 2023 | Sotyktu |
| Verrica Pharmaceuticals INC. | $19.33 | 2025 | Ycanth |
| Aclaris Therapeutics, INC. | $19.13 | 2019 | |
| Merck Sharp & Dohme LLC | $18.98 | 2019 | |
| Ucb, INC. | $14.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Blumenstrauch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.